



NEXALIS
THERAPEUTICS

2026 Annual General Meeting

29 May 2026



WELCOME AND AGENDA

Online attendees

- If you have an IT-related issue, please click on the “Raise Hand” button
- If there is a question relating to the resolution, shareholders can ask questions by clicking on the Q&A button and typing in your question

Agenda

- Resolution 1
 - Poll on Resolution 1
- Resolutions 2 to 9
 - Resolution 2 will be contingent on whether Resolution 1 receives >25% votes against)
 - Resolutions 3 and 6 have been withdrawn
- Formal Meeting Close

2025 FINANCIAL STATEMENTS

To consider and receive the financial statements of the Company for the year ended 31 December 2025, consisting of the Financial Report and the Reports of the Directors and Auditor.

As required by Section 317 of the Corporations Act, the financial statements of the Company for the year ended 31 December 2025 and the accompanying director's report and auditor's report are tabled before the Meeting.

Neither the Corporations Act nor the Company's Constitution requires a vote on the financial statements.

Shareholders may ask questions about the financial statements, including conduct of the audit.

RESOLUTION 1

To consider and, if thought fit, to pass with or without amendment, the following Resolution as a non-binding ordinary resolution:

“That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company’s annual financial report for the financial year ended 31 December 2025.”

Valid Proxies Received	Votes	% Votes
For	14,612,541	100.00%
Open	0	0.00%
Against	0	0.00%
Abstain	19,949,999	
Excluded	1,326,881	

Poll on Resolution 1



Poll opened by the Chair

Click on “For”, “Against” or “Abstain”

Shareholders and visitors who are not voting, click “Skip Poll”

Poll closed by the Chair

Results will be tallied whilst the Chair convenes a short break

RESOLUTION 2

If less than 25% of the votes cast on Resolution 1 are voted against adoption of the Remuneration Report, the Chair will withdraw Resolution 2.

To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution:

“That, for the purposes of section 250V(1) of the Corporations Act and for all other purposes, approval is given for:

- a) the Company to hold another meeting of Shareholders within 90 days of the date of this Meeting (Spill Meeting); and*
- b) all Vacating Directors to cease to hold office immediately before the end of the Spill Meeting; and*
- c) resolutions to appoint persons to offices that will be vacated pursuant to (b) to be put to vote at the Spill Meeting.”*
- d) “That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of*

Valid Proxies Received	Votes	% Votes
For	11,308,541	98.08%
Open	0	0.00%
Against	1,530,881	11.92%
Abstain	23,049,999	
Excluded	0	

RESOLUTION 3

This resolution has been withdrawn

RESOLUTION 4



To consider and, if thought fit, to pass with or without an amendment, the following Resolution as a special resolution:

“That for the purposes of ASX Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in ASX Listing Rule 7.1A.2 and otherwise on the terms and conditions set out in the Explanatory Statement.”

Valid Proxies Received	Votes	% Votes
For	4,426,881	12.33%
Open	0	0.00%
Against	31,462,540	87.67%
Abstain	0	
Excluded	0	

RESOLUTION 5

To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution:

“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to the equivalent of \$85,848 of Share Rights in lieu of Directors’ Fees for the period 1 January 2026 to 31 December 2026 to Sean Williams, Non-Executive Director of the Company (or his nominee) on the terms and conditions set out in the Explanatory Statement.”

Valid Proxies Received	Votes	% Votes
For	35,105,332	100.00%
Open	0	0.00%
Against	0	0.00%
Abstain	784,089	
Excluded	0	

RESOLUTION 6

This resolution has been withdrawn

RESOLUTION 7

To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution:

“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to the equivalent of \$50,400.00 of Share Rights in lieu of Directors’ Fees for the period 1 January 2026 to 31 December 2026 to Anthony Fitzgerald, Non-Executive Director of the Company (or his nominee) on the terms and conditions set out in the Explanatory Statement.”

Valid Proxies Received	Votes	% Votes
For	35,105,332	100.00%
Open	0	0.00%
Against	0	0.00%
Abstain	784,089	
Excluded	0	

RESOLUTION 8

To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution:

“That, for the purposes of Listing Rule 7.4 and for all other purposes, shareholders ratify the issue 6,900,000 Placement Shares and 3,450,000 Placement Options subscribed for and issued to the Tranche 1B Placement Participants on the terms and conditions set out in the Explanatory Statement.”

Valid Proxies Received	Votes	% Votes
For	35,685,421	99.43%
Open	0	0.00%
Against	204,000	0.57%
Abstain	0	
Excluded	0	

RESOLUTION 9

To consider and, if thought fit, to pass with or without an amendment, the following Resolution as an ordinary resolution:

“That, for the purposes of Listing Rule 7.4 and for all other purposes, shareholders ratify the issue of 780,000 Shares at \$0.025 per Share on the terms and conditions set out in the Explanatory Statement.”

Valid Proxies Received	Votes	% Votes
For	35,685,421	99.43%
Open	0	0.00%
Against	204,000	0.57%
Abstain	0	
Excluded	0	

Poll on Resolutions 2 to 9

Poll opened by the Chair

Click on “For”, “Against” or “Abstain” on each resolution

Shareholders and visitors who are not voting, click “Skip Poll”

Poll closed by the Chair

Results will be released on the ASX following the meeting

Meeting formally closed



General Q&A

**Thank you for your attendance at
today's meeting**

T: +61 3 9070 1221

E: investors@nexalistherapeutics.com

W: <https://www.nexalistherapeutics.com>

